the critical role of ppar in human malignant melanomappar在人类恶性黑色素瘤的关键作用.pdfVIP

Hindawi Publishing Corporation PPAR Research Volume 2008, Article ID 503797, 5 pages doi:10.1155/2008/503797 Review Article The Critical Role of PPARγ in Human Malignant Melanoma 1 2 1 ¨ 1 Christian Freudlsperger, Udo Schumacher, Siegmar Reinert, and Jurgen Hoffmann 1 Department of Oral and Maxillofacial Plastic Surgery, Tubingen University Hospital, Osianderstrasse 2-8, ¨ 72076 Tubingen, Germany ¨ 2 Department of Anatomy II: Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany Correspondence should be addressed to Christian Freudlsperger, christian.freudlsperger@med.uni-tuebingen.de Received 28 February 2008; Accepted 21 April 2008 Recommended by Dipak Panigrahy The past 30 years have only seen slight improvement in melanoma therapy. Despite a wide variety of therapeutic options, current survival for patients with metastatic disease is only 6–8 months. Part of the reason for this treatment failure is the broad chemoresistance of melanoma, which is due to an altered survival capacity and an inactivation of apoptotic pathways. Several targetable pathways, responsible for this survival/apoptosis resistance in melanoma, have been described and current research has focused on mechanism inactivating these pathways. As PPARγ was shown to be constitutively active in several tumour entities and PPARγ agonists extent strong anticancer effects, the role of PPARγ as a possible target for specific anticancer strategy was investigated in numerous studies. However, only a few studies have fo